A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
NVP has several properties that make it an attractive candidate for antiretroviral therapy to interrupt HIV-1 transmission in the intrapartum and early postpartum period. The pharmacokinetic profile suggests that NVP would be rapidly absorbed by the mother and transferred to the infant in utero when given during labor and delivery. The HIV-1 antiviral activity is rapid with significant reduction in plasma virus occurring within a few days of drug administration. In addition, NVP has been shown to penetrate cell-free virions and inactivate virion-associated reverse transcriptase (RT) in situ...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- You may be eligible for this study if you:
- • Are an HIV-positive pregnant woman.
- • Have been pregnant for at least 28 weeks.
- • Are at least 13 years of age (consent of parent or guardian is required if under 18).
- • Exclusion Criteria
- You will not be eligible for this study if:
- • You intend to breast-feed.
- • You are allergic to benzodiazepines (a type of tranquilizer).
- • You have a liver disorder.
- • You have received nonnucleoside reverse transcriptase inhibitors (NNRTIs), a class of anti-HIV drugs.
- • You refuse to take ZDV.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
La Jolla, California, United States
Los Angeles, California, United States
San Francisco, California, United States
Washington, District Of Columbia, United States
Miami, Florida, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
New York, New York, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Memphis, Tennessee, United States
Houston, Texas, United States
San Juan, , Puerto Rico
Newark, New Jersey, United States
Durham, North Carolina, United States
New Orleans, Louisiana, United States
Worcester, Massachusetts, United States
Birmingham, Alabama, United States
Patients applied
Trial Officials
Dorenbaum A
Study Chair
Sullivan JL
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials